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Summary: a- and γ-enolase isoenzyme substance concentrations were measured in serum and plasma from
healthy subjects and from 174 patients with different solid tumours. While α-enolase was found to be
increased in the plasma of patients with tumours of quite different origin, γ-enolase apparently reflected
malignancies of the neuroendocrine System. Before the beginning of the cytotoxic therapy γ-enolase was
increased above the upper limit of the reference r nge (10 μg/l) in 27/27 patients (100%) suffering from small
cell lung cancer. Most patients with squamous cell carcinoma of the lung or with prostatic cancer exhibited
normal γ-enolase, while both tumour types produced high plasma substance concentrations of the a-
isoenzymes of enolase.
Wertigkeit der Enolase-Isoenzyme als Tumormarker
Zusammenfassung: Die Substanzkonzentrationen von a- und γ-Enolase-Isoenzym wurden im Serum und
Plasma von Gesunden und 174 Patienten mit unterschiedlichen, soliden Tumoren bestimmt. W hrend sich
die α-Enolase-Formen als relativ unspezifisch, d. h. bei unterschiedlichen Tumoren im Plasma erh ht fanden,
zeigten die γ-Isoenzyme maligne Erkrankungen des neuroendokrinen Systems relativ spezifisch an. Bei einem
Kollektiv von 27 Patienten mit kleinzelligem Lungen-Karzinom fand sich vor der Therapie in 100% der F lle
ein Anstieg der γ-Enolase ber den oberen Referenzwert (10 Hg/l). Patienten mit Plattenepithel-Karzinom
der Lunge und solche mit Prostata-Karzinomen hatten in der Regel normale γ-Enolase-, dagegen erh hte a-
Enolase-Substanzkonzentrationen im Plasma.
Introdiiction studied and characterized by Marangos* group (2).
Cells related to the amine precursor uptake and de- Recently it was found that small cell lung carcinoma
carboxylation (APUD) System (1) share several com- cells also express APUD ceU-specific markers such s
mon properties, which include the ability to produce bombesin, L-dopa decarboxylase and γ-enolase (3).
and secrete peptides, the presence of storage vesicles The first report by Carney et al. (4) that γ-enolase is
and a similar enzyine and isoenzyme pattern. One of elevated to a high degree in the serum of most small
the marker proteinsforthis System is the γ-isoenzyme cell lung cancer patients was confirmed by others
of enolase (neuron-specific enolase, NSE) extensively (5 -14), but it became evident that patients suffering
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from other malignancies may also exhibit increased
γ-enolase in serum. Furthermore, high levels of a-
enolase were reported for some small cell lung cancer
patients (4, 5). Therefore we investigated the speci-
ficity of a- and γ-enolase isoenzymes in plasma sam-
ples from a large group of patients diagnosed with
different types of solid malignant tumours.
Methods
Two different assay techniques were used for the detennination
of enolase isoenzymes, a solid phase immuno-bioluminescence
assay procedure (SIBA) recently described by our group (7)
and a commercially available radioimmunological assay (6, 10)
(NSE-RIA, Pharmacia Freiburg, Gennany). For the biolumi-
nescence test System, enolase isoenzymes were prepared from
human brain s described (14). Polyclonal antisera against a-
and γ-enolases were raised in rabbits (Chinchilla bastards),
purified by affmity chromatography and coated onto polysty-
rene tubes. Enolase catalytic activity flxed to the antibody-
coated tubes was measured in a combined assay using pyruvate
kinase and the luciferin-luciferase System (7). Besides the αα
and γγ isoenzymes, a dimeric hybrid form, αγ, is also present
in several tissues s, well s in serum or plasma, and it cross-
reacts to a certain extent with the respective anti a- or anti γ-
antibodies. The respective isoenzyme catalytic activities were
measured specifically s follows: for detennination of αα-eno-
lase catalytic activity samples were first incubated in tubes
coated with afiinity purified anti-γ antibodies. This resulted in
a total extraction of αγ- and γγ-isoenzymes s demonstrated in
separate experiments with the respective purified isoenzymes.
The samples were then transferred to anti-a-coated tubes and
the catalytic activity measured by the combined biolumines-
cence System. For γγ-enolase the procedure was performed vice
versa. αγ-Enolase catalytic activity was calculated by subtract-
ing the sum of the specifically determined αα- and γγ-enolase
catalytic activities from the total enolase activity measured in
uncoated tubes. Specific catalytic activities measured in such a
way were referred to s αα-, αγ- and γγ-enolase activities or
calculated substance concentrations. Since this procedure was
too laborious for routine use in further studies we measured the
αα and αγ and/or the γγ- and αγ-isoenzyme catalytic activities
together in the respective coated tubes. In this case catalytic
activities or calculated substance concentrations were given
with the single Symbol α or γ.
The bioluminescence assay measures enzyme catalytic activities.
For comparison with the radioimmunological assay, which was
performed in parallel, and with data in the literature, mostly
obtained with specific protein determinating methods such s
enzyme- or radioimmuno-assays, we had to transform the cata-
lytic activity values into enzyme substance concentrations. Since
we did not know the specific catalytic activities of the native
enolase isoenzymes, i. e. in plasma, we calculated the enzyme
substance concentrations on the basis of the specific catalytic
activities of our purified isoenzyme preparations (αα-enolase:
90 kU/g of protein; γγ-enolase: 50 kU/g of protein). Since
the αγ-hybrid form was not purified to homogeneity, enzyme
substance concentrations, calculated from combined measure-
ments of αα/αγ- or γγ/αγ catalytic activities, are assumed to be
only approximate. The radioimmunological assay was per-
formed according to the manufacturer's instructions (NSE,
Pharmacia). Measurements were done in serum or heparinized
plasma.
A correlation of γ-enolase values in 106 plasma samples ob-
tained with both methods (SIBA and RIA) yielded y = -4 2
+ 0.97 x; r = 0.884. In 17/19 plasma samples from patients
with small ccll lung cancer both methods revealed elevated γ-
enolase and similar results. With the exception of the data in
table l, all other figures and tables show only γ-enolase subst-
ance concentrations determined radioimmunologically by use
of the Pharmacia assay (RIA), while all of the α-enolase subst-
ance concentrations were calculated from our bioluminescence
assay (SIBA).
The intra-(n = 20) and inter-(n = 14)assay coefficients of Varia-
tion at cut off point concentrations were 3.4% and 8% for the
RIA and 8% and 13% for the SIBA, respectively. Addition of
purified αα-enolase and γγ-enolase to the respective assay Sys-
tems resulted in a near 100% recovery without any cross-
reactivity.
Classification of patients
In all patients (n = 174) the diagnosis of the respective solid
tumours was confirmed histologically, and immunohistochemi-
cally if necessary. According to the WHO Histological Typing
of Lung Tumours, the classification of small cell carcinoma
includes oat cell carcinoma, intennediate -cell type and com-
bined oat cell carcinoma; squamous cell carcinoma includes s
a variant the spindle cell carcinoma; adenocarcinoma consists
of acinar adenocarcinoma, pap lary adenocarcinoma, bron-
chiolo-alveolar carcinoma and solid carcinoma with mucus
formation; large cell carcinoma includes giant cell carcinoma
and clear cell carcinoma. When mixed type carcinomas are
found, the predominate cell type determines the classification.
Before the Start of cytotoxic chemotherapy, 27 patients with
small cell lung carcinoma were classified with respect to the
extent of the disease. In 8 patients the disease was limited
(tumour localized in one hemithorax and/or ipsilateral supra-
clavicular lymphnodes) and in 19 patients the disease was
extensive. The number of clinically detected metastatic sites,
confirmed by brain or abdomen scan, bone marrow biopsy,
and ultrasound was recorded. Patients were treated intra-
venously with a combination chemotherapy consisting pf adria-
mycin (50 mg/m2 of body surface), cyclophosphamide (1000
mg/m2 of body surface) and oncovin (2 mg) every three weeks
(ACO-scheme).
Patients with limited disease received a prophylactic cranial
Irradiation and were randomized for ehest Irradiation with
0 Gy, 30 Gy and 50 Gy. When progression occurred, tre tment
was changed to Cisplatin VP 16 (40 mg/m2 of body surface)
for two days and etoposide (100 mg/m2 of body surface) for
three days intravenously every three weeks. A complete remis-
sion was defined s a total clinical and r diological involution
of the tumour.
Results
Enolase isoenzymes in serum and plasma
from healthy subjects
Table l summarizes the values for the different isoen-
zymes in serum and plasma from healthy subjects. In
general, values obtained either by separate determina-
tions of the different isoenzyme αά, αγ and γγ (Part
A) or by combined detection of a- or γ-isoenzymes,
i.e. αα/αγ or γγ/αγ (Part B), in serum:are higher
than those from in plasma. This holds true for both
methods used (SIBA and RIA) and is consistent with
data in the literature (5, 11).
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Tab. l. Enolase isoenzymes in serum and plasma frora healthy
subjects.
A Plasma
mean ± SD
r nge
Serum
mean ± SD
r nge
αα-Enolase
(Mg/i)
SIBA
(n = 40)
24 ± 10
2-50
56 ± 17
20-95
αγ-Enolase
(μβ/1)
SIBA
(n = 40)
6.0 ± 3.2
2 ±15
11 4- 4
4 - 1 7
γγ-Enolase
(μ§/1)
SIBA
(n = 40)
3.3 ± 1.5
0.5- 7
8 ± 2.8
2 - 1 6
cc-Enolases γ-Enolases (μg/l)
B Plasma
mean ± SD
r nge
Serum
mean ± SD
r nge
(WU
SIBA
(n = 40)
28 + 13
2 - 7 0
84 ± 29
40- 150
SIBA
(n = 40)
7.1 ± 2.1
1 - 12
28 + 9.3
7 - 4 2
RIA
(n = 20)
4.8 ± 1.1
2 - 8
10.9 ± 3.0
6 - 1 7
Tab. 2. Cases with elevated enolase values in various tumours
and diseases.
1\imour
Small cell lung carcinoma
Squamous cell carcinoma (lung)
Adeno carcinoma (lung)
Large cell carcinoma (lung)
Breast cancer
Colonic carcinoma
Carcinoma of the rectum
Prostatic carcinoma
Ewing sarcoma
Teratoma
Merkel cell sarcoma
Neuroblastoma
Gastric carcinoma
Pancreatic carcinoma
Thyroid carcinoma
Bladder carcinoma
Sarcoma of the scrotum
Oesophageal carcinoma
Laryrigeal carcinoma
Lymph ma,
Lymphogranuloma (Hodgkin)
Histiocytoma
Seminoma
Hyperaephroma
Cholangioma
Meningioma
SchwannomsL
Pheochromocytoma
Islet cell carcinoma
Nesidioblastosis
Islet cell adenoma (insulinoma)
8/19
16/16
3/10
3/3
4/14
0/8
1/6
4/4
l/l
l/l
0/1
l/l
0/3
2/2
l/l
l/l
0/1
i/i
1/2
0/1
0/1
i/i
o/i
2/2
0/1
l/l
0/1
n.d.
n.d.
n.d.
n.d.
65/75
2/16
3/10
1/3
4/14
1/8
1/6
0/4
l/l
l/l
l/l
2/2
1/3
0/2
o/i
o/i
l/l
o/i
1/2
0/1
0/1
o/i
0/1
0/2
l/l
0/1
Λ ΙΛ0/1
l/l
0/1
0/1
0/10
Enolase isoenzymes in plasma from patients
suffer ing from different malignant t umour s
Plasma samples from 174 patients with different tu-
mours were investigated. Results for small cell lung
carcinoma (n = 75), squamous lung carcinoma
(n = 16), adenocarcinoma of the lung (n = 10), large
cell carcinoma (n = 3), breast cancer (n = 14), co-
lonic carcinoma (n = 8), carcinoma of the rectum
(n = 6), prostatic carcinoma (n = 4) and some
special endocrine tumours (n = 6) are summarized
in figure 1. The patients listed in table 2 and figure l
were not classified with respect to tumour degree or
to stage of therapy. The cut-off point was set at 50
μg/l and 10 μg/l for a- and γ-enolase, respectively.
For all other tumours (n = 32), listed in table 2, but
not demonstrated in figure l, normal or near normal
(< 20 μg/l) γ-enolase concentrations were found,
while in some patients α-enolase was slightly elevated.
a-enolases*) γ-enolases*) „
*) Gases with elevated values/total cases; n.d. = not detected.
Fig. 1. a- and γ-enolase isoenzymes in plasma from tumour
patients
The shaded area represents the reference r nge found
in healthy subjects (tab. 1). α-Enolase concentrations
(open symbols) are calculated from bioluminescence
measurements (see Methode); γ-enolase concentration
(closed symbols) are deterrained radioimmunologically.
Carcinoma of the rectum, o, o; colonic carcinoma, Δ,
Δ; last column: neuroblastoma, Δ, Δ; Merkel cell
sarcoma, o, o; Ewing sarcoma, o, D tcratoma, V, V;
pheochromocytoma, x.
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γ-EnoIase concentrations were increased in 65/75
plasma samples from unselected small cell hing carci-
noma patients (87%). It should be noted, however,
that all of the 10 patients with normal γ-enolase
concentrations were under cytotoxic therapy. a-Eno-
lase was measured in 19 of the small cell hing carci-
noma patients and increased values were found in 11
of 19 (58%). Patients with other types of malignant
lung tumours in general exhibited normal or only
slightly increased γ-enolase concentrations. Thus 2/16
(13%) patients with squamous carcinomas, 2/10
(20%) with adenocarcinomas and 1/3 with large cell
carcinomas had elevated plasma γ-enolase.
High levels of α-enolase, however, were found in all
(16/16) plasma samples from patients with squamous
cell carcinoma and in all (3/3) large cell carcinoma
patients, but only in 3 out of 10 (30%) with adenocar-
cinoma.
Two of the fourteen patients with breast cancer had
slightly increased γ-enolase in plasma, while in 4/14
α-enolase was found above the reference r nge. Two
of the fourteen patients with colonic cancer or carci-
noma of the rectum had slightly elevated γ-enolase,
while in all of these patients α-enolase in plasma was
found within the reference r nge. The four patients
with prostatic cancer exhibited a different pattern, i. e.
normal γ-enolase and elevated α-enolase in plasma. In
the last column of figure l, the enolase values for six
patients with different malignancies are shown, i. e.
two cases of neuroblastoma, one Ewing sarcoma, one
Merkel cell sarcoma, one pheochromocytoma and
one teratoma. Patients with islet cell carcinoma
(l case), nesidioblastosis (l case) or insulinoma (10
adenomas) exhibited normal γ-enolase levels (tab. 2,
data not shown in fig. 1).
Figure 2 shows the correlation between a- and γ-
enolase concentrations in plasma from patients with
squamous cell carcinoma (n = 16) and small cell lung
carcinoma (n = 19). Fourteen out of sixteen patients
with squamous cell carcinoma exhibited elevated <x-
enolase, but γ-enolase was normal, indicating that
there was also no increase in αγ-enolase. Four out of
nineteen patients with small cell lung carcinoma had
high γ-enolase, but normal α-enolase, while in plasma
from most of the small cell lung carcinoma patients
(13/19) high levels of a- s well s γ-isoenzymes were
found.
Twentyseven patients out of the whole group of small
cell lung carcinoma patients (n = 75) were classified
with respect to the tumour degree before beginning
of the cytotoxic therapy. Eight were in a limited stage
of disease, 19 in an advanced stage of disease. γ-
Enolase values obtained in both groups before ther-
10 50 100
γ-Enolase. subst nce concentrqtion [/ig/l] 1000
Fig. 2. Comparison of a- and γ-enolase isoenzymes in plasma
from patients with small cell lung carcinoma (ο, η = 19)
or squamous cell carcinoma (o, n = 16).
α-Enolase concentrations are calculated from biolunuV
nescence meas feinents (see Methods); γ-enolase con-
centrations are determined radioimmunologic lly.
Patients with small cell lung carcinoma were not selected
with respect to disease extent. The shaded area gives
the reference r nge found in healthy subjects (tab. 1).
apy were statistically different: limited disease, mean:
40 μg/l, r nge: 28-66 μg/l; extensive disease, mean:
187 μg/l, r nge: 14-446 μg/l; p < 0.001 (Studenfs t-
test). All of these 27 patients had increased γ-enolase
values in plasma at the beginning of therapy. In the
plasma of 6 patients with limited disease and 7
patients with extensive disease, measurements of γ-
enolase were performed during extensive chemother-
apy over a period from 3 to 20 weeks (fig. 3). In 5
patients with limited disease, γ-enolase values de-
clined in accordance with the clinical criteria of remis-
sion, while one patient changes from a limited to an
extensive diseased stage. In 5/7 patients with extensive
disease the transient resp nse to therapy was accom-
panied by a fall of γ-enolase concentrations in
plasma, while in two non-responders γ-enolase in-
creased.
Discussion
The search for and research pn proteins specific f r
definite cells or tissue types has been intensified dur-
ing recent years. The basis for this approach is the
concept that the differentiated functions of special-
ized cells may be expressed by means of the properties
of the individual proteins.
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Fig. 3. Sequential plasma γ-enolase determinations in smali cell lung cancer patients with limited disease (a) and extensive disease
(b)
a) limited disease: patients during remission, o-o; patient in tumour progression from limited to extensive disease,
0-Δ;
b) extensive disease: patients during response to therapy, A - Δ; patients after relapse and tumour progression, A -n;
for details of the chemotherapy see the method section: ACO = adriamycin/cyclophosphamide/oncovin.
Therefore fresh attention has been paid to specific
isoenzyme patterns. The dimeric glycolytic enzyme,
enolase, consists of three distinct subunits a, , and
γ and the respective hybrid forms (2). While the -
subunit s a part of -isoenzyme or the a -hybrid
seems to be relatively muscle-specific (15), the a-
subunit in its different forms is widely distributed in
mammalian tissues (16). The γγ-isoenzyme has been
identified with the 14-3-2 nervous system-specific pro-
tein (16, 17) and the two isoenzyme forms, αγ and
γγ, have been immunohistochemically localized in
neurons (19), neuroendocrine cells (19) s well s in
most blood cells (11, 20). The terai neuron-specific
enolase (NSE) is therefore misleading. Furthermore,
some confusion exists in the literature, because cer-
tain authprs use the name neuron-specific enolase
only for the homologous dimeric isoenzyme γγ-eno-
lase, while others describe both αγ and γγ-enolase by
this term. Since the tissue distribution of the αγ-
hybrid is not exactly known, and most of the poly-
clonal γ-antisera used for immunochemical detection
cross-react with both γ-forms, we prefer the classifica-
tion by Greek letters. Consequently we use the de-
scription of a dimeric enzyme, i. e. αα, αγ or γγ, if
the isoenzymes are determined separately, while the
subu it specification is used for combined measure-
ments of the respective subunits.
As demonstrated in table l enolase isoenzyme levels
are considerably higher in serum than in plasma. This
is true for all isoenzymes, irrespective whether the
isoenzymes are determined separately or by combined
measurements of the different subunit forms. Since
platelets contain high amounts of αα, αγ and γγ-
isoenzymes (11, 21), specific enzyme proteins might
be released from aggregated thrombocytes during
clotting, thereby resulting in higher serum levels. We
therefore prefer measurements in plasma instead of
serum. Due to the enolase content of red blood cells,
even slight haemolysis contributes to a significant
increase in plasma or serum levels, especially of the
α-enolase forms, s shown by Day & Thompson (21).
The bioluminescence assay (SIBA) measures enzyme
catalytic activities. Substance concentrations calcu-
lated on the basis of our purified isoenzyme prepara-
tions (9) are in fairly good agreement with data re-
ported in the literature and obtained with enzyme
protein determination methods. Thus Kalo et al. (11)
reported 20 ± 6, 4.1 ± 1.4 and 1.5 + 0.4 μ^ for
αα-, αγ- and γγ-enolase, respectively, in plasma and
59 ± 27, 8.0 ± 3.1 and 2.0 ± 0.9 μg/l in serum.
Other authors (4—6) found values between l and
7 μg/l for the γ-enolases in plasma and somewhat
higher values in serum (tab. 3). This distribution
J. Clin. Chem.€lin. Biochem. / Vol. 24,1986 / No. 12
1014 Gerbitz et al.: Enolase isocnzymes s tumour markers
Tab. 3. Frcquency of raised γ-enolase levels in Jung tumour patients before treatment.
Author (ref.)
Carney et al. (4)
Arivoshi et al. (5)
A'flroetal. (11)
Aroney et al. (8)
Johnson et al. (9)
Esscher et al. (12)
Akoun et al. (13)
Cooper et al. (10)
P hlrnan et al. (6)
This study
Upper limit of
reference r nge
(Mg/1)
12
7.5
~ 14
12
20
12
10
13.5
13
10
Small cell lung
limited
15/38 (39)
—
—
—23/39 (59)
34/48 (72)
6/16 (38)
25/38 (66)
33/47 (70)
8/8 (100)
cancer (%)
extensive
49/56 (87)
—
-r
—45/54 (83)
54/55 (98)
22/27 (79)
34/39 (87)
56/58 (97)
19/19 (100)
all cases
63/94 (67)
12/20 (65)
8/9 (89)
7/7 (100)
68/93 (73)
88/103 (85)
28/43 (65)
59/77 (77)
89/105 (85)
27/27 (100)
Non small cell
lung cancer
_
6/54 (11)
—
• r 2 /2 (100)
—13/51 (27)
2/14 (14)
16/94 (17)
8/41 (20)
5/29 (17)
pattern of the enolase isoenzymes is only valid for
healthy subjects and can be altered dramatically in
serum or plasma samples from tumour patients, s
shovvn by Kalo et al. (15) and our group (14).
γ-Enolase isoenzymes have also been detected immu-
nohistochemically in neuroendocrine tumours (22,
23), s well s in carcinomas of the lung (3, 24, 25).
Carney and coworkers were the first (4) to use the
determination of γ-enolases s a marker for assessing
the extent of the disease, and response to therapy of
small cell lung cancer. In the meantime several reports
have confirmed their results (5 — 14). However i t be-
came evident that patients with small cell lung carci-
noma s well s patients with non-small cell lung
carcinoma may exhibit high concentrations of γ-eno-
lase in plasma or serum (3-8, 10). These results,
confirmed by our measurements, possibly reflect
some uncertainties in the exact histological classifica-
tion, caused by mixed type carcinomas (24—26). Al-
ternatively, during tumour progression, non small cell
lung cancers cells could also develop the ability to
produce γ-enolase isoenzymes s a result of de-differ-
entiation processes. In this connection, it is interesting
that Schmechel et al. (27) reported a switch from non-
neuronal to neuronal enolase during development of
neurons.
About one half of the small cell lung cancer patients
also exhibited high levels of α-enolase in plasma.
Separate determinations of the isoenzymes αα and
αγ (14) showed, in most cases, elevations of both
isoenzymes. Patients suffering from squamous cell
carcinoma or large cell carcinoma had increased
levels of α-enolase in plasma, while raised levels of
γ-enolase were found only in a small percentage.
Further studies are required to clarify the question
of whether measurements of a- and γ-isoenzymes in
plasma are clinically relevant for the diagnosis of
different types of lung cancer.
When stage of disease and therapy were not taken
into consideration, 87% of the small cell lung carci-
noma patients had elevated γ-enolase substance con-
centrations in plasma. However, all of the 10 patients
exhibiting normal γ-enolase values in plasma were
under therapy. In 27 patients out of the whole small
cell lung carcinoma collective we were able to measure
γ-enolase in plasma before the beginning of the ther-
apy. The increase in γ-enolase was dependent on the
stage of disease before therapy, but all of these
patients exhibited γ-enolase values in plasma above
the upper level of the reference r nge. Thus the sensi-
tivity of γ-enolase s a marker for small cell lung
carcinoma approaches 100%. The fact that our data
on sensitivity are even higher than those reported
in the literature (3-13, tab. 3) might be partially
explained by the relatively low cut-off point (10 μg/l)
used in our study, s well s by the use of plasma
instead of serum. Serial determinations of γ-enolase
in plasma samples from some patients receiving cyto-
toxic therapy for small cell lung carcinoma showed
a correlation between the initial clinical response and
the γ-enolase levels. This was true for patients who
responded to therapy, and the reverse was true for
non-responders. Progression of the disease, s well
s emergence of therapeutic resistance, was usually
accompanied by an increase of γ-enolase values.
However, in two of our small cell lung carcinoma
patients γ-enolase normalized during the remission
period and remained within the reference r nge, al-
though these two patients died soon after from pro-
gressive disease. Both patients had been typed s
small cell lung carcinoma by histology after bronchial
biopsy. Post mortem histology, however, revealed a
change of the tumour type, in one case a large cell
carcinoma, in the other case a carcinoid. Possibly
both cases reflected the phenomenon that the usual
emergence of resistance to cytotoxic therapy seems
to be accompanied by transition of small cell lung
J. Clin. Chem. Clin. Biochem. / Vol. 24,1986 / No. 12
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carcinoma to other cellular phenotypes (28, 29).
Interestingly, Minna's group (30, 31) recently re-
ported that the loss of endocrine characteristics from
small cell lung carcinoma cells maintained in cell
culture was paralleled by a 20 —80 fold amplification
of oncogenes of the myc-family.
Among the 31 different types of solid tumours investi-
gated in this study only those listed in figure l showed
varying degrees of elevation of γ-enolase in plasma,
while slightly raised plasma α-enolase values were
sometimes found in other tumours. Four cases with
prostatic cancer had γ-enolase levels within the refer-
ence r nge, but they showed increased α-enolase. This
result needs further confirmation. Two cases with
neuroblastoma and one with a pheochromocytoma
showed elevated plasma γ-enolase levels, consistent
with reports in the literature (6, 33, 34). The high
levels of γ-enolase found in the single cases suffering
from Merkel cell sarcoma or teratoma might be ex-
plained by the fact that these tumours also belong to
the endocrine System (35). Malignant and benign
tumours of the islets of Langerhans generally did not
lead to an increase of γ-enolase in plasma.
Conclusion
In conclusion, elevated α-enolase isoenzyme were
found in the plasma of patients suffering from dif-
ferent solid tumours. Obviously α-enolase isoenzymes
can only be considered s unspecific tumour markers.
γ-Enolase, however, can serve s a relatively specific
neuroendocrine tumour marker, especially with re-
spect to small cell lung cancer. In this connection we
confirm that the commercially available radioimmu-
nological assay for γ-enolases, used in this study, is
rapid, precise and accurate. Detailed studies in close
co-operation between pathologists, clinical chemists
and physicians seem to be necessary to clarify the
question of whether separate determinations of a-
and γ-enolases in plasma could be helpful in the
differentiation of the various forms of lung cancers.
Such studies are now in progress in our laboratory.
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